Sorafenib in Advanced Hepatocellular Carcinoma
In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than f...
Publications
View AllSarcopenia: revised European consensus on definition and diagnosis
EWGSOP2's updated recommendations aim to increase awareness of sarcopenia and its risk. With these new recommendations, EWGSOP2 calls for healthcare professionals who treat pati...
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Abstract The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous ad...
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
Cardiovascular diseases (CVDs), principally ischemic heart disease (IHD) and stroke, are the leading cause of global mortality and a major contributor to disability. This paper ...
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel. (...
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
Over the past decade, the Nomenclature Committee on Cell Death (NCCD) has formulated guidelines for the definition and interpretation of cell death from morphological, biochemic...
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy
In this case series of critically ill patients with laboratory-confirmed COVID-19 admitted to ICUs in Lombardy, Italy, the majority were older men, a large proportion required m...
The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines
A DELPHI consensus exercise was completed and an updated and improved SCARE Checklist is now presented.
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who h...
Affiliated Researchers
Institution Info
- Type
- healthcare
- Country
- IT
- Publications
- 40
- Citations
- 123,404
External Links
Identifiers
- ROR
- https://ror.org/04tfzc498